Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The conversation is about finding a reliable source for RU58841 in middle Europe, as the user had issues with previous suppliers. Anageninc is suggested as a potential source.

The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

A user found a successful hair loss treatment using a combination of finasteride, dutasteride, minoxidil, and RU58841. They plan to switch to a purely topical regimen with finasteride, RU58841, and minoxidil.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

The conversation is about a person considering making their own topical finasteride to avoid side effects from oral use. They discuss potential methods and ingredients, including cayenne pepper extract, rosemary, and coconut oil, and seek advice on effectiveness and alternatives like light therapy or dermarolling.

The conversation discusses the effectiveness of the AutumnValley Anti-hair Loss Complex Pack for hair growth and hair loss prevention. The original poster is considering adding it to their regimen, which already includes Minoxidil, finasteride, and RU58841.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.

People are pessimistic about PP405, believed to be Jxl-069, due to doubts about its effectiveness and delivery method. Some think it doesn't work, while others blame the vehicle used for application.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

Significant hair regrowth was achieved using RU58841, minoxidil, and microneedling during a high-dose steroid cycle. The user reported no side effects from RU58841 and plans to continue the regimen.

A user is combining RU58841 with a topical formula containing finasteride, dutasteride, minoxidil, triamcinolone, caffeine, and other ingredients. They have just started using it and report no side effects so far.

A user is creating a custom topical hair regrowth serum using minoxidil, bimatoprost, tretinoin, castor oil, and hyaluronic acid. They are also using dutasteride, oral minoxidil, and castor oil in their current regimen.

The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.

The conversation is about making and selling RU58841 scalp lotion by mixing the powder with ethanol and propylene glycol. The user is considering selling it as a lotion due to import restrictions in their country.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

A YouTuber known for skepticism is hinting at a promising new hair regrowth treatment. The treatment details are undisclosed, but it is not related to known substances like RU58841.

The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.